biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
23:37 One-time gene therapy for severe child epilepsy cut seizures, maker says✦23:33 Alzheimer's drug cut brain plaque but did not slow decline; maker stops it✦23:32 First patient gets Japan's stem-cell treatment for Parkinson's, maker says✦17:39 Tuberculosis vaccine cut brain tangles linked to dementia in mice✦17:38 22-person trial will test a weight-loss drug on brain-aging blood tests✦17:36 Daily pill helped children with the most common dwarfism grow faster✦17:34 FDA drops top warnings on 3 menopause patches without outside advisers✦11:39 Geriatrics group lays out how to give older adults weight-loss drugs safely✦23:37 One-time gene therapy for severe child epilepsy cut seizures, maker says✦23:33 Alzheimer's drug cut brain plaque but did not slow decline; maker stops it✦23:32 First patient gets Japan's stem-cell treatment for Parkinson's, maker says✦17:39 Tuberculosis vaccine cut brain tangles linked to dementia in mice✦17:38 22-person trial will test a weight-loss drug on brain-aging blood tests✦17:36 Daily pill helped children with the most common dwarfism grow faster✦17:34 FDA drops top warnings on 3 menopause patches without outside advisers✦11:39 Geriatrics group lays out how to give older adults weight-loss drugs safely
← All story threadsSTORY THREAD

Acumen's Alzheimer's antibody sabirnetug.

1 report so far. New developments are added to this thread as they happen.

  1. Oct 30, 2026
    MID-STAGE TRIAL MISSES ITS GOAL; DRUG IS STOPPEDCompany results · 542 people

    Alzheimer's drug cut brain plaque but did not slow decline; maker stops it

    In a 542-person trial, Acumen's antibody lowered amyloid plaque on brain scans but did not slow memory or daily-life decline, so the company is ending the drug's development.